Cross Shawn

Chief Financial Officer

Cross Shawn has filed 6 SEC Form 4 filings (15 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Apr 25, 2026.

On the most recent filing, Cross Shawn is listed as Chief Financial Officer at Pacira BioSciences, Inc. Inside the rolling window, Cross Shawn reported no open-market purchases and 7 open-market sales totaling $1.5M in PCRX. The largest disclosed transaction in the window is a sale of 15,896 PCRX shares on Dec 9, 2025, worth $398K.

Companies traded

Other insiders at PCRX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$1.5M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
PCRXSale$326KApr 25SEC ↗
PCRXSale$194KApr 22SEC ↗
PCRXSale$71KApr 22SEC ↗
PCRXSale$38KApr 22SEC ↗
PCRXSale$398KDec 11SEC ↗
PCRXSale$229KDec 11SEC ↗
PCRXSale$266KNov 13SEC ↗
Showing 1–7 of 7
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Cross Shawn made?

Cross Shawn has filed 6 SEC Form 4 filings (15 transaction rows) across 1 company since 2025.

Which companies does Cross Shawn trade?

Cross Shawn has filed SEC Form 4 disclosures for 1 company, including PCRX.

When was Cross Shawn's most recent SEC Form 4 filing?

Cross Shawn's most recent SEC Form 4 filing on Tracefour is dated Apr 25, 2026.

What is Cross Shawn's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Cross Shawn is listed as Chief Financial Officer.

What is Cross Shawn's total buy and sell value in the current window?

Inside the rolling retention window, Cross Shawn bought $0 and sold $1.5M based on SEC Form 4 filings.

What was Cross Shawn's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 15,896 PCRX shares on 2025-12-09, worth $398K, per SEC Form 4 filings.